Verrica Pharmaceuticals (VRCA) Non Operating Income (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Non Operating Income of $33000.0 for Q1 2026, up 102.05% year-over-year from $16332.8 in Q1 2025, and up 103.74% quarter-over-quarter from -$882000.0 in Q4 2025.
Verrica Pharmaceuticals (VRCA) Non Operating Income (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Non Operating Income history runs 10 years deep, the most recent figure standing at $33000.0 for Q1 2026.
- In Q1 2026, Non Operating Income rose 102.05% year-over-year to $33000.0; the TTM figure through Mar 2026 stood at -$4.1 million (up 61.52% YoY), while the FY2025 annual figure was -$5.7 million, up 46.52% from the prior year.
- Non Operating Income for Q1 2026 stood at $33000.0, up from -$882000.0 in the prior quarter.
- The five-year high for Non Operating Income was $626000.0 in Q2 2023, with the low at -$4.8 million in Q4 2024.
- The 5-year median for Non Operating Income is -$1.3 million (2025), against an average of -$1.2 million.
- Peak annual rise in Non Operating Income reached 159.79% in 2023, while the deepest fall reached 629.75% in 2023.
- Verrica Pharmaceuticals' Non Operating Income stood at $279000.0 in 2022, then slumped by 629.75% to -$1.5 million in 2023, then sank by 224.22% to -$4.8 million in 2024, then surged by 81.59% to -$882000.0 in 2025, then soared by 103.74% to $33000.0 in 2026.
- Business Quant data shows VRCA's Non Operating Income at $33000.0 in Q1 2026, -$882000.0 in Q4 2025, and -$1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | -56,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -56,000.00 |
| Mar 31, 2026 | 33,000.00 |
| Dec 31, 2025 | -882,000.00 |
| Sep 30, 2025 | -1.90 Mn |
| Jun 30, 2025 | -1.31 Mn |
| Mar 31, 2025 | -1.61 Mn |
| Dec 31, 2024 | -4.79 Mn |
| Sep 30, 2024 | -2.16 Mn |
| Jun 30, 2024 | -1.98 Mn |
| Mar 31, 2024 | -1.73 Mn |
| Dec 31, 2023 | -1.48 Mn |
| Sep 30, 2023 | -885,000.00 |
| Jun 30, 2023 | 626,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Dec 31, 2022 | 279,000.00 |
| Sep 30, 2022 | -1.37 Mn |
| Jun 30, 2022 | -1.05 Mn |
| Mar 31, 2022 | -1.06 Mn |
| Dec 31, 2021 | -1.07 Mn |
| Sep 30, 2021 | -1.06 Mn |